Immunic 경영진

경영진 기준 점검 3/4

Immunic CEO는 Daniel Vitt, Apr2019 에 임명되었습니다 의 임기는 7.08 년입니다. 총 연간 보상은 $2.31M, 27.1% 급여 및 72.9% 보너스(회사 주식 및 옵션 포함)로 구성됩니다. 는 $586.25K 가치에 해당하는 회사 주식의 0.29% 직접 소유합니다. 경영진과 이사회의 평균 재임 기간은 4.8 년과 5.5 년입니다.

핵심 정보

Daniel Vitt

최고경영자

US$2.3m

총 보수

CEO 급여 비율	27.05%
CEO 재임 기간	7.1yrs
CEO 지분 보유율	0.3%
경영진 평균 재임 기간	4.8yrs
이사회 평균 재임 기간	5.5yrs

최근 경영진 업데이트

Recent updates

분석 기사 • Oct 17

Here's Why We're A Bit Worried About Immunic's (NASDAQ:IMUX) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

분석 기사 • Oct 13

Here's Why Immunic (NASDAQ:IMUX) Must Use Its Cash Wisely

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...

분석 기사 • Jun 27

Will Immunic (NASDAQ:IMUX) Spend Its Cash Wisely?

We can readily understand why investors are attracted to unprofitable companies. For example, although...

Seeking Alpha • Oct 20

Immunic sinks ~74% after hours as phase 1b psoriasis trial fails to separate from placebo

Immunic (NASDAQ:IMUX) on Thursday said a phase 1b trial of its psoriasis treatment IMU-935 failed to separate from placebo, as measured by a reduction in the severity of the psoriatic lesions in the patients. Shares of the micro-cap clinical-stage biopharma plunged 73.7% to $2.49 after hours. A pre-planned interim analysis of the early-stage trial found a greater decrease than expected in the so-called Psoriasis Area and Severity Index (PASI) in the placebo arm. The PASI is a widely used instrument in psoriasis trials that evaluates and grades the severity of psoriatic lesions and the patient's response to treatment. The trial enrolled a total of 41 patients who were randomized to get 150 mg once-daily and 150 mg twice-daily doses of IMU-935, along with placebo. "At this point, the company only has access to very limited information. The interim analysis only revealed mean values at group-level up to the end of the four-week treatment period. Immunic does not yet have access to unblinded individual patient data," the company said in a statement. IMUX expects to continue IMU-935 development in psoriasis.

Seeking Alpha • Oct 10

Immunic stock gains on $60M oversubscribed PIPE financing

Immunic (NASDAQ:IMUX) shares gained as much as 21% premarket on Monday after the clinical-stage biopharmaceutical company announced a $60M oversubscribed private placement equity financing. The company entered into a securities purchase agreement with select accredited investors and certain existing investors to issue and sell an ~8.69M shares of its common stock at $4.35/share and pre-funded warrants to purchase up to 5,096,552 common shares at $4.34/pre-funded warrant share. The pre-funded warrants will be immediately exercisable at $0.01 per share of common stock and remain exercisable until exercised in full. Gross proceeds from the equity financing is estimated to be around $60M. The financing is expected to close on Oct 12, 2022. Net proceeds will be used to fund Immunic's (IMUX) ongoing clinical development of its three lead product candidates, vidofludimus calcium (IMU-838), IMU-935 and IMU-856, and for other general corporate purposes. Proceeds, along with current cash, cash equivalents and marketable securities, is expected to fund operating and capital expenditures into Q4/2024.

Seeking Alpha • Aug 04

Immunic GAAP EPS of -$0.72 in-line

Immunic press release (NASDAQ:IMUX): Q2 GAAP EPS of -$0.72 in-line. Cash and Cash Equivalents as of Q2 $88.1 million.

분석 기사 • Jul 27

Here's Why Immunic (NASDAQ:IMUX) Must Use Its Cash Wisely

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

CEO 보수 분석

Daniel Vitt의 보수는 Immunic의 수익에 비해 어떻게 변했나요?
날짜	총 보수	급여	회사 수익
Mar 31 2026	n/a	n/a	-US$104m
Dec 31 2025	US$2m	US$625k	-US$97m
Sep 30 2025	n/a	n/a	-US$103m
Jun 30 2025	n/a	n/a	-US$102m
Mar 31 2025	n/a	n/a	-US$96m
Dec 31 2024	US$3m	US$610k	-US$101m
Sep 30 2024	n/a	n/a	-US$97m
Jun 30 2024	n/a	n/a	-US$95m
Mar 31 2024	n/a	n/a	-US$98m
Dec 31 2023	US$1m	US$585k	-US$94m
Sep 30 2023	n/a	n/a	-US$129m
Jun 30 2023	n/a	n/a	-US$127m
Mar 31 2023	n/a	n/a	-US$125m
Dec 31 2022	US$3m	US$520k	-US$120m
Sep 30 2022	n/a	n/a	-US$85m
Jun 30 2022	n/a	n/a	-US$83m
Mar 31 2022	n/a	n/a	-US$79m
Dec 31 2021	US$2m	US$399k	-US$93m
Sep 30 2021	n/a	n/a	-US$83m
Jun 30 2021	n/a	n/a	-US$77m
Mar 31 2021	n/a	n/a	-US$70m
Dec 31 2020	US$1m	US$381k	-US$44m
Sep 30 2020	n/a	n/a	-US$41m
Jun 30 2020	n/a	n/a	-US$36m
Mar 31 2020	n/a	n/a	-US$39m
Dec 31 2019	US$2m	US$202k	-US$35m

보상 대 시장: Daniel의 총 보수(USD2.31M)는 US 시장에서 비슷한 규모 기업의 평균(USD1.59M)보다 높습니다.

보상과 수익: Daniel의 보상은 지난 1년 동안 회사 실적과 일치했습니다.

CEO

Daniel Vitt (57 yo)

7.1yrs

재임 기간

US$2,311,272

보수

Dr. Daniel Vitt, PhD has been the Chief Executive Officer of Immunic, Inc. since April 2019 and also served as its President until July 12, 2024. He is also managing director of Immunic Research GmbH in Ha...

리더십 팀

이름	직위	재임 기간	보수	지분
Daniel Vitt	CEO & Director	7.1yrs	US$2.31m	0.29% $ 586.2k
Jason Tardio	COO & President	1.8yrs	US$1.21m	0.0092% $ 18.7k
Glenn Whaley	Chief Financial Officer	6.1yrs	US$1.07m	0.070% $ 142.9k
Hella Kohlhof	Chief Scientific Officer	9.3yrs	데이터 없음	데이터 없음
Jessica Breu	Vice President of Investor Relations & Communications	no data	데이터 없음	데이터 없음
Inderpal Singh	General Counsel	4.9yrs	데이터 없음	데이터 없음
Patrick Walsh	Chief Business Officer	4.6yrs	데이터 없음	데이터 없음
Werner Gladdines	Chief Development Officer	1.8yrs	데이터 없음	데이터 없음
Michael A. Panzara	Chief Medical Officer	less than a year	데이터 없음	데이터 없음

4.8yrs

평균 재임 기간

54yo

평균 나이

경험이 풍부한 관리: IMUX의 경영진은 경험이 있음으로 간주됩니다(평균 재임 4.8 년).

이사회 구성원

이름	직위	재임 기간	보수	지분
Daniel Vitt	CEO & Director	7.1yrs	US$2.31m	0.29% $ 586.2k
Barclay Phillips	Lead Independent Director	6.5yrs	US$171.98k	0.11% $ 233.3k
Michael Bonney	Chair of the Board	no data	데이터 없음	데이터 없음
Tamar Howson	Independent Director	6.6yrs	US$149.82k	0.11% $ 233.3k
Jorg Neermann	Independent Director	7.1yrs	US$156.98k	0.15% $ 299.2k
Paul Utz	Member of Scientific Medical Advisory Board	5.5yrs	데이터 없음	데이터 없음
Duane Nash	Director	7.3yrs	US$982.95k	0.026% $ 53.9k
Bruce Sands	Member of Scientific Medical Advisory Board	5.5yrs	데이터 없음	데이터 없음
Fred Lublin	Member of Scientific Medical Advisory Board	5.5yrs	데이터 없음	데이터 없음
Richard Rudick	Independent Director	3.1yrs	US$149.48k	0.17% $ 344.6k
Jon Congleton	Independent Director	less than a year	데이터 없음	데이터 없음
Simona Skerjanec	Independent Director	1.8yrs	US$149.14k	데이터 없음

5.5yrs

평균 재임 기간

62yo

평균 나이

경험이 풍부한 이사회: IMUX의 이사회는 경험이 있음으로 간주됩니다(평균 재임 5.5 년).

기업 분석 및 재무 데이터 상태

데이터	최종 업데이트 (UTC 시간)
기업 분석	2026/05/31 05:16
종가	2026/05/29 00:00
수익	2026/03/31
연간 수익	2025/12/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
기업 재무제표	10년	손익계산서 현금흐름표 대차대조표	SEC 양식 10-K SEC 양식 10-Q
분석가 컨센서스 추정치	+3년	재무 예측 분석가 목표주가	분석가 리서치 보고서 Blue Matrix
시장 가격	30년	주가 배당, 분할 및 기타 조치	ICE 시장 데이터 SEC 양식 S-1
지분 구조	10년	주요 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
경영진	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발	10년	회사 공시	SEC 양식 8-K

^* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

Immunic, Inc.는 18명의 분석가가 다루고 있습니다. 이 중 9명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가	기관
George Farmer	BMO Capital Markets Equity Research
William Wood	B. Riley Securities, Inc.
Tyler Bussian	Brookline Capital Markets

Immunic 경영진

경영진 기준 점검 3/4

핵심 정보

최근 경영진 업데이트

Immunic, Inc. Announces Chief Executive Officer Changes

Immunic, Inc. Appoints Michael W. Bonney as Chair of the Board of Directors, Effective May 16, 2026

Immunic, Inc. Chief Medical Officer Changes, Effective April 24, 2026

Immunic, Inc. Appoints Jon Congleton to Its Board of Directors, Effective March 27, 2026

Immunic, Inc. Plans Transition of Daniel Vitt from CEO

Immunic, Inc.'s Subsidiary Gliomic Therapeutics Inc. Announces Executive Appointments, Effective January 1, 2026

Recent updates

Immunic, Inc. Announces Chief Executive Officer Changes

Price target decreased by 10% to US$44.67

Immunic, Inc. Appoints Michael W. Bonney as Chair of the Board of Directors, Effective May 16, 2026

Immunic, Inc. Chief Medical Officer Changes, Effective April 24, 2026

Immunic, Inc. Appoints Jon Congleton to Its Board of Directors, Effective March 27, 2026

Price target increased by 11% to US$5.00

No longer forecast to breakeven

New major risk - Negative shareholders equity

Immunic, Inc. announced that it has received $200.010837 million in funding from a group of investors

Immunic, Inc. Prioritizes Completion of the Ongoing Phase 3 Ensure Clinical Trials and Initiation of A Phase 3 Clinical Program in Primary Progressive Multiple Sclerosis

Immunic, Inc. announced that it expects to receive $200 million in funding from a group of investors

Immunic, Inc. Plans Transition of Daniel Vitt from CEO

New minor risk - Share price stability

Immunic to Present Additional Phase 2 Calliper Trial Data Foridofludimus Calcium At the Actrims Forum 2026, Reinforcing Its Potential in Progressive Multiple Sclerosis

Nasdaq Grants Immunic, Inc. an Additional 180-Day Grace Period to Regain Compliance with the Bid Price Rule

Immunic, Inc.'s Subsidiary Gliomic Therapeutics Inc. Announces Executive Appointments, Effective January 1, 2026

Forecast to breakeven in 2028

New major risk - Shareholder dilution

New minor risk - Profitability

We're A Little Worried About Immunic's (NASDAQ:IMUX) Cash Burn Rate

Price target decreased by 11% to US$6.83

Immunic, Inc. Presents Key Vidofludimus Calcium Data At the 41st Congress of ECTRIMS, Highlighting Its Potential in Multiple Sclerosis

Immunic, Inc. Receives Notice of Allowance for United States Patent Protecting Vidofludimus Calcium's Dose Strengths in Progressive Multiple Sclerosis

New major risk - Financial position

No longer forecast to breakeven

Immunic, Inc. Receives Notice of Nasdaq Non-Compliance with Minimum Bid Price Requirement

Immunic, Inc. Reports New, Positive Long-Term Open-Label Extension Data from Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis

Immunic Post-Readout: Reiterating Strong Buy As Big Drop Appears Unwarranted

Independent Director recently bought US$100k worth of stock

Immunic, Inc. Announces Completion of Enrollment for Both Phase 3 ENSURE Trials in Relapsing MS and Presents Additional Data Underlining Positive Outcome of Phase 2 Calliper Trial in Progressive MS

Price target decreased by 8.3% to US$12.55

Immunic, Inc. has announced a Derivatives Offering.

New major risk - Negative shareholders equity

New minor risk - Share price stability

Immunic, Inc. Announces Positive Data from Phase 2 Calliper Trial of Nurr1 (Nurr1) Activator,Idofludimus Calcium (Imu-838) in Patients with Progressive Multiple Sclerosis

Immunic: A Strong Buy With Imminent Data Readout That Should Send Shares Higher

Immunic, Inc., Annual General Meeting, Jun 04, 2025

Immunic, Inc. has completed a Follow-on Equity Offering in the amount of $5.1 million.

Immunic, Inc. has filed a Follow-on Equity Offering in the amount of $5.1 million.

Price target increased by 7.0% to US$13.12

Immunic, Inc.'s Oral IMU-856 Demonstrates Dose-Dependent Increase of GLP-1 in Celiac Disease Patients and Corresponding Effects in Preclinical Testing

New minor risk - Market cap size

Independent Director recently bought US$100k worth of stock

No longer forecast to breakeven

Immunic, Inc. to Report Q3, 2024 Results on Nov 07, 2024

We're Keeping An Eye On Immunic's (NASDAQ:IMUX) Cash Burn Rate

Immunic, Inc. Announces Positive Outcome of Interim Analysis of Phase 3 Ensure Program of Vidofludimus Calcium in Relapsing Multiple Sclerosis

Immunic, Inc. Announces First Patient Enrolled in Investigator-Sponsored Phase 2 Clinical Trial ofidofludimus Calcium in Patients with Post COVID Syndrome

Price target decreased by 13% to US$11.90

New major risk - Financial position

New minor risk - Share price stability

New minor risk - Profitability

No longer forecast to breakeven

New major risk - Financial position

Immunic, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Immunic, Inc. Appoints Simona Skerjanec as Member of the Board

Immunic, Inc. Appoints Jason Tardio as Chief Operating Officer and President

New minor risk - Profitability

No longer forecast to breakeven

Immunic, Inc. to Report Q1, 2024 Results on May 08, 2024

Immunic Announces Publication of Extended Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis in the Peer Reviewed Journal, Neurology® Neuroimmunology & Neuroinflammation

Immunic, Inc., Annual General Meeting, Jun 11, 2024

Price target decreased by 32% to US$9.00

Immunic, Inc. to Report Fiscal Year 2023 Results on Feb 22, 2024

New major risk - Shareholder dilution

Here's Why We're A Bit Worried About Immunic's (NASDAQ:IMUX) Cash Burn Situation

Immunic, Inc. announced that it expects to receive $240 million in funding from BVF Partners L.P., Avidity Partners, LLC, Janus Henderson Investors, Soleus Capital, RTW Investments, LP, Adage Capital Management, L.P.

Forecast to breakeven in 2026

New major risk - Financial position